Mechanisms of antifungal resistance

Revista Iberoamericana de Micologia

Volumn 14, Issue 2, 1997, Pages 44-49

  Bossche, Hugo Vanden ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Allylamines; Azole antifungals; Flucytosine; Griseofulvin; Morpholines; Polyenes; Resistance

Indexed keywords

EID: 0001074757     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Vanden Bossche H, Marichal P, Odds FC. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 1994; 2: 393-400.
2. Dekker J. Development of resistance to modern fungicides and strategies for its avoidance In: Lyr H (Ed.). Modern selective fungicides - Properties, applications, mechanisms of action. Jena, Gustav Fisher Verlag, 1995: 23-28.
3. Vanden Bossche H, Warnock DW, Dupont B, et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Myc 1994; 32 (Suppl. 1): 189-202.
4. Polak A, Hartman PG. Antifungal chemotherapy - are we winning? Progress Drug Res 1991; 37: 181-269.
5. Medoff G, Kobayashi GS, Kwan CN, Schlessinger D, Venkov P. Potentiation of nfampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B. Proc Natl Acad Sci 1972; 69: 196-199
6. Georgopapadakou N, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies Antimicrob Agents Chemother 1996; 40: 279-291.
7. Powderly WG, Kobayashi GS, Herzig GP, Medoff G Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988; 84: 826-832.
8. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980; 18: 158-163.
9. Manchal P, Vanden Bossche H. Mechanisms of resistance to azole antifungals. Acta Biochim Pol 1995; 42: 509-516.
10. Sangfard D, Ischer F, Monod M, Bille J Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic -inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-2305.
11. Pommer E-H Morpholine fungicides and related compounds. In. Lyr H. (Ed.). Modern selective fungicides - Properties, applications, mechanisms of action. Jena, Gustav Fisher Verlag, 1995: 163-183
12. Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmac Ther 1995, 67 79-100.
13. Troke PF In vitro and experimental in vivo activities of fluconazole against some fungi causing cutaneous mycoses. In: Rippon JW, Fromtling RA (Eds.). Cutaneous antifungal agents New York, Marcel Dekker, 1993: 199-214.
14. Johnson EM, Davey JK, Szekely A, Warnock DW. Itraconazole susceptibilities of fluconazole and resistant isolates of five Candida species. J Antimicrob Chemother 1995; 36: 787-793.
15. Manchal P, Gorrens J, Coene M-C, Le Jeune L, Vanden Bossche H. Origin of differences in susceptibility of Candida kruse to azole antifungal agents. Mycoses 1995; 38: 111-117.
16. Marriott M.S, Richardson K. The discovery and mode of action of fluconazole. In: Fromtling RA (Ed.). Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona, JR Prous, 1987: 81-92
17. Horsburgh CR, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 1983; 74 (Suppl. 1B): 23-29.
18. Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. Sabouraudia 1984; 22: 53-63.
19. Hitchcock CA, Barett-Bee K, Russell NJ. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol 1986; 132: 2421-2431.
20. Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835-2841.
21. Johnson EM, Richardson MD, Warnock DW. In vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother 1984, 13: 547-558.
22. Warnock DW, Johnson EM, Richardson MD, Vickers CFH. Modified response to ketoconazole of Candida albicans from a treatment failure Lancet 1983; i: 642-643
23. Hitchcock CA, Barrett-Bee KJ, Russell NJ, Inhibition of 14α-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole. J Med Vet Mycol 1987; 25: 329-333.
24. Howell SA, Mallet AT, Noble WC. A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and azole-resistant strains. J Appl Bacteriol 1990; 69: 692-696.
25. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly ED. Mode of action and resistance to azole antifungals associated with the formation of 14α-methyl-ergosta-8,24(28)-dien-3-6α-diol. Biochem Biophys Res Commun 1995; 207: 910-915.
26. Kelly SL, Rowe J, Watson PF Molecular genetic studies on the mode of action of azole antifungal agents. Biochem Soc Trans 1991; 19: 796-798.
27. Geber A, Hitchcock CA, Swartz JE et al. Deletion of the Candida glabrata ERG3 and ERG11 genes effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 1995; 39: 2708-2717.
28. Smith KJ, Warnock DW, Kennedy CTC et al. Azole resistance in Candida albicans. J Med Vet Mycol 1986; 24: 133-144.
29. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PAJ. Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antiifungals. Biochem Soc Trans 1990; 18: 56-59
30. Joseph-Home T, Carelli A, Hollomon D, Loeffler RST, Kelly SL. Investigation of azole resistance in the Ustilago maydis sterol demethylase mutant Erg 40. Pestic Sci 1995; 44: 33-38
31. Joseph-Horne T, Hollomon D, Loeffler RST, Kelly SL. Altered P450 activity associated with direct selection for fungal azole resistance. FEBS Lett 1995; 374: 174-178.
32. Sanglard D, Kuchler K, Ischer F, Pagani J-L, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
33. Balzi R, Goffeau A. Genetics and biochemistry of yeast multidrug resistance. Biochim Biophys Acta 1994; 1187: 152-162
34. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems Microbiol Rev 1996; 60: 575-608.
35. Becker JM, Henry LK, Jiang WD, Koltin Y. Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infect Immun 1995; 63: 4515- 4518.
36. Fling ME, Kopf J, Tamarkin A, Gorman JA, Smith HA, Koltin Y. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991; 227: 318-329.
37. Prasad RP, Dewergifosse P, Goffeau A. Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995, 27: 320-329.
38. Warnock DW, Burke J, Cope NJ, Johnson EM, Van Fraunhofer NA, Williams EW. Fluconazole resistance in Candida glabrata. Lancet 1988; 2 (8623) 1310.
39. Vanden Bossche H, Manchal P, Odds FC, Le Jeune L, Coene M-C Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36: 2602-2610
40. Vanden Bossche H, Marichal P, Odds FC, Luyten W. Mechanisms of resistance to azole antifungals. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, American Society for Microbiology, 1993: 1586.
41. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993; 37: 1962-1965
42. Clark FS, Parkinson T, Hitchcock CA, Gow NAR Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996; 40: 419-425.
43. Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agents Chemother 1997; 41: 410-414.
44. De Waard MA, Groeneweg H, Van Nistelrooy JGM. Laboratory resistance to fungicides which inhibit ergosterol synthesis in Penicillium italicum. Neth J Plant Pathol 1982; 88: 99-112.
45. De Waard MA, Van Nistelrooy JGM. Toxicity of fenpropimorph to fenarimol-resistant isolates of Penicillium italicum Neth J Plant Pathol 1982; 88: 231-236.
46. Lamb DC, Corran A, Baldwin BC, Kwong-Chung J, Kelly SL Resistant P450 51A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett 1995; 368: 326-330.
47. Langcake P, Kuhn PJ, Wade M. The mode of action of systemic fungicides. In. Hutson DH, Roberts TR (Ed.). Progress in pesticide biochemistry and toxicology. Vol. 3. Chichester, John Wiley, 1983: 1-109.
48. Polak A. Mode of action studies. In: Ryley JF (Ed). Chemotherapy of fungal diseases. Berlin, Springer-Verlag, 1990: 153-182.